Liminatus Pharma, Inc. (LIMN) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2025)

-$10.2M

Total Assets (FY2025)

$512.8K

Total Equity (FY2025)

-$9.8M

Cash Flows from Operating Activities (FY2025)

-$10.0M

Source: Liminatus Pharma, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.